One in Two Patients With Metastatic Melanoma Alive After 5 Years One in Two Patients With Metastatic Melanoma Alive After 5 Years

With the combination of ipilimumab and nivolumab, 50% of patients are still alive after 5 years, a survival rate remarkably higher than that seen with either agent alone.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news